ParkourSC Acquires Quartic, PacBio Partners with Verily, CAS Data Arrives in Microsoft Copilot

October 26, 2026 | Carterra and AstraZeneca collaborate on lab-in-the-loop drug discovery; Ultima Genomics is selected for an 80,000-sample UK Biobank immune profiling study; Hansa Biopharma taps Cradle for AI protein design; Genedata adds NVIDIA protein design models to its discovery workflows; Dotmatics reaches Databricks Gold status; new products from Revvity, Benchling, and Nabsys; and more.

Genedata, a Danaher company, announced that it has added RFD4-Proteina, a binder design model introduced at NVIDIA GTC Berlin, to its AI-enabled discovery workflows as an ecosystem partner. In the workflow, scientists define target characteristics and required properties using Genedata's AI co-scientist, and NVIDIA's open protein design models then generate and evaluate candidate binders within Genedata. Candidates move to lab testing, and results are linked back to the original designs to refine and rank the next round. Genedata provides orchestration, governance and a scientific data foundation for deploying NVIDIA BioNeMo open models while maintaining data lineage and traceability. Within Danaher's autonomous laboratory initiative, these capabilities form a closed-loop framework in which each experimental outcome informs the next design cycle. Press release.

CAS, a division of the American Chemical Society, announced that its CAS Connections connector is now available in Microsoft Copilot, giving Copilot customers access to the CAS Content Collection and CAS Newton, an agentic AI tool for science. CAS and Microsoft built the integration mainly for pharmaceutical, life sciences and chemical organizations, bringing CAS-curated knowledge into the Copilot apps R&D teams already use. In Word, researchers can verify a compound's CAS Registry Number and structure, check reaction conditions and reagent availability, and cite sources; in Teams, they can check whether a substance appears in patent literature; and in PowerPoint, they can add patent landscape information traceable to CAS content. CAS Connections launched in June 2026 and also connects to electronic lab notebooks, LIMS, discovery platforms and enterprise AI tools. The connector is listed in the Microsoft Marketplace. Press release.

Ultima Genomics announced the commercial launch of paired-end sequencing on its UG200 Series and the availability of Solaris 2.0 Max sequencing consumables at the ASHG 2026 Annual Meeting in Montréal. Solaris 2.0 Max delivers up to 20 billion reads per wafer, double the output of existing Solaris workflows, and enables a $60 human genome. Paired with the UG200 Ultra, it supports up to 60,000 30x whole human genomes per year on one instrument. It runs on the UG200 Series and UG100 platforms, and 10-billion and 5-billion reads-per-wafer versions are planned for early 2027. Paired-end reads sequence both ends of each DNA fragment, improving read mapping in repetitive and structurally complex regions, and are aimed at germline whole genome sequencing and structural variant detection. Press release.

Revvity has launched Signals LabGistics, an AI-based scientific workflow orchestration solution from its Revvity Signals Software business, designed to connect and coordinate processes, workflows, and tasks from early discovery through manufacturing. The software turns plain-language descriptions and standard operating procedures into coordinated workflows. It targets delays caused by fragmented systems and manual handoffs, especially during technology transfer from R&D to manufacturing. Multi-tier execution, centralized data and real-time monitoring let scientists and managers track workflow status and spot bottlenecks. The platform works with existing laboratory and manufacturing systems, supports GxP compliance for pharma and biotech, and limits regulatory overhead for specialty chemical and materials science companies. Availability in the U.S., Canada, Europe and Japan is expected in December 2026. Press release.

PacBio and Verily Health announced a multi-year strategic collaboration to integrate PacBio HiFi long-read sequencing with Verily Pre, Verily Health's governed data and AI platform, pairing long-read genomic data with real-world clinical data at population scale. The resulting AI-ready clinico-genomic datasets are intended for biomedical discovery, AI model training and deployment. Verily Health will configure Pre Workbench, which serves more than 20,000 researchers, as the governed environment for aggregating, analyzing and curating HiFi genomic datasets, and the companies plan to use Verily Pre's trusted agentic environment for model training and inference. PacBio HiFi whole-genome sequencing workflows already run end-to-end within Verily Pre. The integration is to expand over the collaboration to support larger long-read programs across research organizations, biopharma and population genomics. Press release.

Ultima Genomics announced that its UG200 Sequencing Platform has been selected to support a large-scale immune profiling study with IMU Biosciences and UK Biobank. The study combines IMU's High Definition Immunology platform, the BD FACSDiscover Cell Analyzer, Waters Corporation's BD Rhapsody single-cell multiomics platform and Ultima's sequencing to add a high-resolution immune data layer and an AI foundational dataset to UK Biobank. The initial cohort is 80,000 blood samples from UK Biobank participants, with the aim of expanding to the full 500,000-participant cohort. The project begins in 2026, and data will be returned to UK Biobank for approved researchers studying how immune variation relates to disease risk, progression, treatment response and health outcomes. The UG200 was validated with BD Rhapsody in February 2026. Press release.

Nabsys announced the launch of RepX, a repeat expansion analysis pipeline available through its Nabsys Navigator cloud platform. RepX analyzes Electronic Genome Mapping (EGM) data generated on the OhmX Platform to study disease-associated repeat expansions, with the potential to analyze up to 23 loci in a single run. EGM examines individual ultra-long DNA molecules without amplification or ligation, letting researchers assess the distribution of expansion sizes and instability within each allele. RepX uses data from the standard OhmX VOLT Whole Genome Kit, so the same dataset can also support genome-wide structural variant and copy number variant analyses. In Navigator, RepX sits alongside the SV-Discover and SV-Verify tools. The products are for research use only. Press release.

Benchling announced Direct Data Share, an integration with Snowflake that keeps scientific data continuously connected between a company's Benchling and Snowflake environments. Experimental data from Benchling lands in Snowflake as ready-to-query tables that refresh in near real time, while instrument, assay, computational and third-party data in Snowflake can flow back into Benchling alongside the related experiments. IT and data teams complete a one-time setup by connecting a Snowflake account, with no custom export pipeline to build or maintain as the scientific data model changes, and admins control who can start syncs and manage connections. Direct Data Share complements Benchling's AI Connectors, launched earlier in 2026, by supporting continuous, large-scale analysis across millions of rows. It is available in public beta to Benchling customers. Press release.

Benchling also launched Science Foundries, which lets R&D teams run scientific processes end to end with AI agents and scientists working together. Teams choose a process or goal, such as producing proteins, optimizing a lead or improving a manufacturing process, and set which steps agents run and where scientists must approve. Agents execute and monitor work, coordinate handoffs and escalate key decisions using shared scientific data and context. In a high-throughput biologics example, a Foundry uses design, cloning, lab and analysis agents to generate sequences, place CRO orders, send instructions to workcells and analyze results overnight. Parabilis Medicines uses Science Foundries for protein production, screening and lead optimization. Benchling customers can set up their own Science Foundries, starting with a focus area and a conversation with Benchling AI. Press release.

ParkourSC has acquired Quartic, combining ParkourSC's clinical and commercial supply chain AI with Quartic's manufacturing AI into a single platform for regulated life sciences and healthcare. The platform links manufacturing data with clinical, distribution and healthcare data to predict which batches, lots and shipments are at risk and recommend actions such as adjusting a process, rerouting a shipment, prioritizing inventory or accelerating release. Deviation, verification, release, excursion, disposition and regulatory documentation are managed in one environment within predefined guardrails. The platform sits above existing MES, LIMS, QMS, historian and logistics systems rather than replacing them. Reported outcomes include cutting fit-for-use disposition decisions from three days to one minute and 15–20% higher batch yields in biologics manufacturing. Financial terms were not disclosed. Press release.

Carterra, a provider of high-throughput surface plasmon resonance (HT-SPR) platforms for antibody and small molecule drug discovery, announced a research collaboration with AstraZeneca to develop hardware and software for lab-in-the-loop drug discovery. In this approach, AI proposes drug candidates, wet-lab experiments test those predictions, and the resulting data refines the next round of AI-guided design. The collaboration addresses a central barrier to applying AI in structural and biophysical drug discovery: the lack of consistent, comparable experimental data at scale. Carterra's engineering and software teams are working with AstraZeneca scientists and automation experts to build lab systems that generate standardized data at scale, along with software that makes that data usable in AI and machine learning workflows. Press release.

PacBio and TychoBio announced a collaboration to generate full-length RNA data that TychoBio, an AI drug discovery company, will use to train models for designing RNA therapies for rare diseases. TychoBio plans to apply PacBio HiFi sequencing and Kinnex long-read RNA sequencing to more than 10,000 samples to build datasets linking the design of steric blocking antisense oligonucleotides (SBOs) to their transcriptome-wide effects, with plans to extend the approach to siRNA and other RNA-targeting compounds. TychoBio will test candidate therapies and use PacBio sequencing to measure how each one changes the transcriptome across multiple cell types. The resulting data will train models to predict which compounds are most likely to work, how long their effects last and where unintended effects may occur. Press release.

Dotmatics announced that Luma, its Scientific Intelligence Platform, has reached Gold tier status in the Databricks Brickbuilder Partner Network and is now listed on the Databricks Marketplace, expanding a strategic partnership the companies announced in December 2024. The milestones make Luma directly available to more than 20,000 organizations building on Databricks, which can adopt it without separate data infrastructure. Built natively on Databricks, Luma acts as an orchestration layer that continuously ingests instrument outputs, harmonizes them into FAIR-compliant structured data, preserves scientific context from wet lab to dry lab, and keeps a traceable record for analysis, modeling and AI. Luma data sits alongside enterprise data such as manufacturing, quality and clinical systems, and Databricks OpenSharing supports governed exchange with CROs and academic partners. Press release.

Hansa Biopharma announced a partnership with Cradle, a developer of AI-driven protein design and engineering software for biologics. Hansa will use Cradle's end-to-end platform across its discovery pipeline to design, optimize and advance new therapeutic candidates for patients with severe autoimmune diseases. Hansa selected Cradle after evaluating several AI models and vendors. The platform supports the discovery pipeline from hit identification onward, multi-parameter optimization across complex engineering objectives, and active learning from Hansa's own data, intended to accelerate Hansa's lab-in-the-loop process. Hansa focuses on rare IgG-related immunologic conditions. Its lead product, imlifidase, is marketed in Europe as Idefirix and is under FDA review for highly sensitized kidney transplant candidates, with a PDUFA date in December. Financial terms were not disclosed. Press release.